Title: Estimating Excess Mortality Among People Living with HIV/AIDS During the COVID-19 Pandemic in the USA

Running Head: US Excess Mortality Among PWHA During COVID-19

Lindsay M. HALL[1*], Hamed KARAMI[1,2], Gerardo CHOWELL[1,3,*]

[1] Department of Population Health Sciences, Georgia State University, Atlanta, GA, USA

[2]Department of Mathematics and Statistics, Georgia State University, Atlanta, GA, USA

[3]Department of Applied Mathematics, Kyung Hee University, Yongin, 17104, Korea

*Corresponding author. Email: lhall63@student.gsu.edu;gchowell@gsu.edu

Abstract:

Objectives: To quantify the all-cause excess death rate of people living with HIV/AIDS (PWHA) during the multi-year 2020-2022 COVID-19 pandemic in the United States (U.S.), including stratifications by sex, age, race/ethnicity, and region.

Design: Using publicly available data from the CDC NCHHSTP AtlasPlus dashboard, we employed the ensemble n-subepidemic modeling framework (*SubEpiPredict* toolbox). This dynamic, uncertainty-aware approach was used to generate counterfactual forecasts of U.S. deaths among PWHA for 2020–2022.

Methods: The models were calibrated using 12 years of pre-pandemic mortality trends (2008-2019), with the median excess death rate calculated as the difference between forecasted and observed death rates. Results were stratified by age, sex, race/ethnicity, and U.S. region.

Results: Overall excess mortality among PWHA was estimated at 7,783 crude excess deaths (95% prediction interval [PI]: 5,098–10,525), corresponding to 2.77 excess deaths per 100,000 people (95% PI: 1.81–3.75), with the largest burden observed in 2021. Excess death rates were highest among males (3.39), individuals aged 55–64 years (4.94), multiracial populations (12.82), and residents of the Northeast U.S. (4.12). In contrast, the largest absolute number of excess deaths occurred among males (4,692), adults aged 65 years and older (2,560), Black/African American individuals (3,969), and residents of the Southern U.S. (4,025).

Conclusions: These systematic, model-based results reveal stark heterogeneities among PWHA by exposing recent mortality patterns that may not be captured by disease-specific mortality reporting alone. These heterogeneous findings can inform future public health programming and resource allocation and support tailored interventions for vulnerable populations.

Key Words: HIV/AIDS; excess mortality; COVID-19; forecasting; health disparities; United States.

Introduction:

The convergence of two public health crises—COVID-19 and HIV— raises important questions about the intersectional impact of COVID-19 on people living with HIV/AIDS (PWHA), especially within already marginalized groups. Between 2020 and 2022, COVID-19 was listed as an underlying or contributing cause of over one million U.S. deaths—approximately 10.8% of all-cause mortality during that period [1]. Meanwhile, the U.S. mortality rate due to HIV has continued its gradual decline, dropping from 2.6 per 100,000 in 2010 to 1.3 per 100,000 in 2021 [2]. Despite this progress, HIV-related deaths remain disproportionately concentrated among specific populations, particularly males (76%), Black/African American individuals (49%), residents of the South (55%), and adults aged 45 or older (73%) [2]. Examining excess mortality among PWHA during the pandemic—across demographic groups—is essential to understanding potential compounded disparities and to inform more equitable public health responses in the future [3,4].

Evidence for increased mortality risk among PWHA stems from both biological vulnerabilities—such as potential immunosuppression due to low CD4 cell counts [5,6] —and a range of indirect pandemic effects, including reduced access to care and service interruptions [6,7]. Several studies report a moderately increased risk of COVID-19 mortality among people living with HIV (PWH) (Hazard ratios of 1.60 to 2.08) [5,8,9].

Overwhelmed healthcare systems diverted resources away from routine HIV prevention, testing, and treatment, while lockdowns and clinic closures disrupted antiretroviral therapy (ART) adherence and viral suppression efforts—especially in already resource-constrained communities [10,11,4,7]. These indirect effects likely contributed to elevated HIV/AIDS mortality during this period—deaths often termed “second-order deaths”—that may not be fully captured in standard cause-of-death records [7,12]. Viewed through a syndemic lens, the interaction between HIV and COVID-19 extends beyond biological co-infection risks. It encompasses compounding pandemic-related stressors such as visible community health impacts, social-distancing measures, and reduced access to healthcare. This framework underscores the multifactorial vulnerabilities faced by PWHA during overlapping epidemics [13].

Standard cause-of-death records are often insufficient to capture this complexity, as misclassification and underreporting are common during public health emergencies [14,12]. In this context, all-cause excess mortality serves as a more comprehensive metric, capable of capturing both direct and indirect deaths,

including those not explicitly attributed to HIV/AIDS or COVID-19. Previous studies estimating excess deaths have relied on simple mathematical calculations among people living with HIV (PWH) [6,7]. However, they do not include deaths coded among people living with AIDS (PWA), and available stratifications exclude regional variation. Importantly, all these analyses are restricted to the year 2020, capturing only the initial phase of the pandemic and omitting the broader compounding effects of subsequent waves, healthcare disruptions, and policy shifts [15,6,7].

Understanding potential demographic patterns in excess deaths is critical for identifying disparities, informing recovery efforts, and improving future public health preparedness. This study addresses that gap by applying n-sub-epidemic modeling to stratify excess mortality among PWHA in the U.S. across the full pandemic period (2020-2022) by sex, age, race/ethnicity, and region across the full span of years 2019-2022. Moreover, these results will serve as a benchmark for existing excess death estimations [6,7] that utilize simple calculation methods and were limited in scope. Unlike prior studies, which reference historical averages to infer excess deaths, our method compares forecasted and observed death rates within the same year, allowing for more precise and timely estimates. Lastly, through this comparison, these results will also contribute to the growing validation of the modeling framework itself, which has shown past success on forecasting HIV, COVID-19, and mpox [3,16].

In this study, we employ the ensemble n-subepidemic modeling framework to estimate excess mortality among PWHA in the U.S. during the COVID-19

pandemic, stratified by sex, age, race/ethnicity, and geographic region. This approach enables more granular and robust estimates by calibrating to 12 years of pre-pandemic data and incorporating uncertainty through probabilistic forecasts. Our results highlight stark heterogeneities in pandemic-related excess mortality and underscore the importance of tailored equity-informed public health responses. Our study provides the first multi-year, model-based estimates of all-cause excess deaths among people living with HIV during COVID-19, establishing a reproducible benchmark for assessing pandemic-related disparities and health-system resilience. These estimates serve as a benchmark comparison for published excess death estimates and inform future emergency-preparedness planning to guide public health priorities and policies.

Methods:

Data Collection and Preparation

Available yearly all-cause death rates and crude deaths (2008–2022) for PWHA were obtained from the CDC NCHHSTP AtlasPlus dashboard (accessed on February 25th, 2025), which provides overall and one-way stratified mortality data (i.e., stratified by a single demographic variable at a time, such as sex, age group, race/ethnicity, or region). This database compiles de-identified HIV/AIDS surveillance data reported to the CDC through the National HIV Surveillance System (NHSS) by demographic category. Of note, at the time of analysis, death data for 2022 were considered preliminary and based on death data received by the CDC as of December 2023. CDC provides additional data collection details in

their *Technical Notes [17].* Since the data is publicly accessible and de-identified, Institutional review board approval was not required.

Excess Mortality Estimation

To estimate all-cause excess mortality among PWHA during the COVID-19 pandemic, we compared observed deaths during the years 2020–2022 to counterfactual forecasts generated using the ensemble n-sub-epidemic modeling framework [16] calibrated to the pre-pandemic period (2008–2019). Specifically, we computed yearly excess death rates and crude excess deaths by demographic category.

Because AtlasPlus data are available only as overall or one-way stratified summaries, models were fitted separately for each stratum rather than jointly across demographic dimensions; consequently, stratified estimates are internally consistent but not additive across strata. The original dataset distinguished between all-cause deaths of PWH versus PWA; this would be expected to have relevance on mortality rates. Thus, for each demographic category, three separate (3) models were generated: 1) deaths among PWH, 2) deaths among PWA, and 3) combined deaths among PLHA. This approach enabled disaggregated and aggregated assessments across disease indicators.

The dynamic of the n-sub-epidemic framework is described by the following ODE system:

$$\frac{dC_i(t)}{dt} = A_i(t) r_i C_i^{p_i}(t)\left(1 - \frac{C_i(t)}{K_{0_i}}\right), \quad i = 1,2,\dots,n,$$

In this model, C_i represents cumulative number of deaths, r_i denotes growth rate, p_i is scale of growth and K_{0_i} is epidemic size for the i_{th} sub-epidemic, where $1 \leq i \leq n$. Given $A_1(t) = 1$, the indicator function A_i characterizes the onset timing of the rest i_{th} sub-epidemic and is defined by:

$$A_i(t) = \begin{cases} 1 & C_{i-1}(t) > C_{thr} \\ 0 & Otherwise \end{cases}, \quad i = 2,3,\dots,n,$$

Where C_{thr} is called the threshold, triggers sub-epidemic i when $C_{i-1}(t) > C_{thr}$. Therefore, the initial condition in this model is given by $(C_1(0), 0, \dots, 0)$ where $C_1(0)$ is the first reported data. The threshold values C_{thr} are obtained by evenly dividing the cumulative sum of the smoothed signal into the same number of levels as there are data points. This method treats C_{thr} as a series of possible threshold values, allowing the model to be tested at each fixed level instead of estimating the threshold directly from the data. The corrected Akaike Information Criterion (AIC_c) is then used to identify the best-performing sub-epidemic models. Specifically, AIC_cvalues are computed for the best-fitting models corresponding to different C_{thr} values. AIC_c is calculated as follows [18,19]:

$$AIC_c = -2log(likelihood) + 2m + \frac{2m(m+1)}{n_d - m - 1},$$

where m is the total number of data points and n_d is the total number of data points calibrated.

Although annual HIV-related death rates exhibit relatively shallow trends, the n-sub-epidemic framework remains appropriate because its primary purpose here is uncertainty-aware counterfactual forecasting rather than wave detection. Even under approximately linear baselines, the framework provides principled probabilistic estimates against which deviations during 2020–2022 can be formally assessed, with model flexibility constrained (maximum two sub-epidemics) to avoid overfitting.

Models were calibrated using observed death rates from 2008–2019 (baseline period).

Model fitting was conducted using nonlinear least squares, assuming normally distributed errors. We assessed distributional assumptions using residual diagnostics (normal Q–Q plots and residuals versus fitted values). Residuals approximated a normal distribution, with minor departures at the extreme tails consistent with empirical aggregated mortality data. Yearly forecasts of death rates by demographic category were then generated for 2020-2022. Models include a median trendline of death rate, as well as a 95% prediction interval (PI) to capture uncertainty. The 95% prediction interval bounds of the median death rates were used to compute the excess death rate intervals, using previously established methodology [20], as described below.

Let $\hat{y}_t$ represent the forecasted death rate per 100,000 population in year $t \in \{2020, 2021, 2022\}$, and y_t the corresponding observed death rate. The annual excess death rate (EDR) is calculated as:

$$EDR = max(0, y - \hat{y}),$$

where EDR denotes the excess death rate per 100,000 people for year t. The non-negativity constraint reflects the standard interpretation of excess mortality as deaths above an expected counterfactual baseline. Negative deviations, while statistically and biologically plausible, were retained at the model-output level but set to zero for burden estimation to avoid offsetting positive excesses and obscuring cumulative impact. Since our forecasted trend ŷ includes a 95% prediction interval (PI), the lower and upper bounds of the excess death rate are computed as follows:

$$EDR_t^{LB} = max(0, y - \hat{y}_t^{UB}), \quad EDR_t^{UB} = max(0, y - \hat{y}_t^{LB}).$$

Hence, we ensure that the uncertainty from the forecast is propagated into the excess mortality estimates.

To calculate crude excess deaths, each excess death rate was multiplied by the respective population subgroup size N given in the original dataset:

$$CED = EDR \times \left(\frac{N_t}{100{,}000}\right).$$

Lower and upper bounds for crude excess deaths were calculated analogously, using the corresponding bounds of EDR.

$$CED_t^{LB} = EDR_t^{LB} \times \left(\frac{N_t}{100{,}000}\right), \quad CED_t^{UB} = EDR_t^{UB} \times \left(\frac{N_t}{100{,}000}\right).$$

It is worth noting that this method allows for quantifying excess mortality across different demographic groups while incorporating forecast uncertainty. Importantly, excess death rates are interpreted as the additional deaths per 100,000 people beyond expected mortality, capturing both direct and indirect effects of the pandemic.

The n-sub-epidemic framework. A weighted (W) ensemble was derived from the n-sub-epidemic framework to produce all forecasts [16]. This framework aggregates multiple asynchronous sub-epidemic models and creates forecasted trajectories. In this analysis, sub-epidemics are modeled as generalized logistic growth models and assume a maximum of 2 sub-epidemics in the trajectory to reduce overfitting and improve stability, given the limited number of annual observations. Model parameters are estimated using the nonlinear least squares method. To estimate parameters with known uncertainty, 300 bootstrap samples per model were generated using the approach described by Hastie et al. [21].

We constructed two ensemble model variations from the top two ranked models based on AIC_c. The weighted (W) ensemble model utilized relative likelihood to determine the weights of the top two ranked models and the unweighted (UW)

ensemble model assumed equal weight for the top two ranked models. Primary results presented in this study are derived from the weighted ensemble models due to their superior calibration performance.

Analyses were performed using MATLAB (R2023a).

Results:

We focus our findings on the weighted (W) ensemble models, which provide better calibration than unweighted (UW) ensemble models. Nevertheless, the unweighted (UW) results closely mirrored the trends of weighted (W) but with wider uncertainty bounds. Unweighted model results are provided in Supplementary Material Figures 11-15.

Overall patterns:

Weighted (W) models forecast a continued decrease in the death rate from HIV, AIDS, and HIV/AIDS Combined during the pandemic years (Figure 1). However, observed death rates in the forecast period exceed the weighted (W) model's 95% PI for all years across disease categories. The maximum excess death rate for all disease indicator categories occurred in 2021, with HIV at 1.80 [95%PI 1.23-2.39], AIDS at 1.19 [95% PI 0.80-1.61], and HIV/AIDS combined at 2.77 [95%PI 1.81-3.75] excess deaths per 100,000 (Figure 2).

Correspondingly, maximum crude excess deaths in 2021 were among HIV/AIDS Combined at 7793 [5,098-10,525] crude deaths (Supplementary-Figure 5). Residual diagnostics revealed approximately normal distributions with minor deviations at the extreme tails and slight heteroscedasticity at higher fitted values, which are consistent with aggregated population-level mortality data and do not substantially violate the modeling assumptions (Supplementary Figure S16), supporting the validity of the assumed error structure.

By Sex:

Males had the highest excess death rates in all categories. Weighted (W) models forecast a continued decrease in the death rate from HIV, AIDS, and HIV/AIDS Combined (Supplementary-Figure 1) in all sexes. However, observed death rates in the forecast period exceed the weighted (W) model's 95% PI for all years and groups. In addition to Males experiencing higher death rates than Females, Males also experienced higher *excess* death rates than females for all disease indicators. The maximum excess death rate for all groups occurred in 2021, with the highest, Male-Combined, at 3.39 [95%PI 1.69-4.99], excess deaths per 100,000 (Figure 3).

The highest crude excess deaths for all disease indicator categories in 2021 were: Male-Combined at 4,692 [95%PI 2,338-6,907] total crude deaths (Supplementary-Figure 6).

By Age:

Older adults experienced the largest excess death burden during the pandemic period. Weighted (W) models forecast a continued decrease in the death rate from HIV, AIDS, and Combined HIV/AIDS (Supplementary-Figure 2) for age groups under age 55, and a continued increase in age groups 55 and above. Observed death rates in the forecast period exceed the weighted (W) model's 95% PI for most but not all years and groups.

As shown in Figure 4, age group 13-24 exhibited zero excess death rates for all years, with minimal positive 95% PI ranges. The age group with the total highest excess death rate was group 55-64 at 4.94 [95%PI 3.24-6.68] per 100,000 for the Combined HIV/AIDS group. Notably, the timing of peak excess mortality varied by age group. Age groups 25-34 and 35-44 for all disease indicator groups had a maximum excess death rate in 2022. Age groups 45-54, 55-64, and 65+ for all disease indicator groups had a maximum excess death rate in 2021.

The maximum crude excess deaths for all disease indicator categories occurred in year 2021 for age group 65+ Combined at 2,560 [95%PI 1,391-3,616] crude deaths (Supplementary-Figure 7).

By Race:

Black/African American and Multiracial groups experienced the highest race-based disparities. Weighted (W) models forecast a continued decrease in death rate from HIV, AIDS, and Combined HIV/AIDS (Supplementary-Figure 3) for American Indian/Alaska Native, Asian, Black/African American, Hispanic/Latino, and

Multiracial races, and a continued increase in Native Hawaiian/Other Pacific Islander and White races. Observed death rates in the forecast period for most years exceeded the weighted (W) model's 95% PI for all races except for Asian and Native Hawaiian/Pacific Islander races.

As displayed in Figure 5, the maximum excess death rate for all races except for American Indian/Alaska Native occurred in 2021. Multiracial and Black/African American races groups had both the highest death rates and highest excess death rates relative to other races. The race-indicator groups with the overall highest excess death rate were Multiracial-Combined and Black/African American-Combined, at 12.82 [95%PI 5.44-20.38] and 11.42 [95%PI 7.07-16.10] respectively.

The maximum crude excess deaths for all disease indicator categories occurred in year 2021 for the Black/African American-Combined group at 3,969 [95%PI 2,455-5,591] crude deaths (Supplementary-Figure 8).

By Region:

The South and Northeast regions bore the highest mortality burden. Weighted (W) models forecast a continued decrease in death rate from HIV, AIDS, and Combined HIV/AIDS (Supplementary-Figure 4) for all regions. Observed death rates in the forecast period for all years exceeded the weighted (W) model's 95% PI for all regions except for US territories and freely associated states.

Each region's maximum excess death rate occurred in different years, with the Northeast in 2020, South and West in 2021, and Midwest and US territories and

freely associated states in 2022 (Supplementary-Figure 9). The highest excess death rate occurred in the Northeast at 4.12 [95%PI 2.76-5.49] in 2020.

Regarding absolute burden, the maximum crude excess deaths for all disease indicator categories occurred in the year 2021 in the South-Combined group at 4,025 [95%PI 2,450-5,729] crude deaths (Supplementary-Figure 10).

Discussion:

Overall, we estimated excess deaths among PWHA at 7783 crude excess deaths, or a rate of 2.77 excess deaths per 100,000 people, peaking in 2021. The highest excess death rates were observed among males (3.39), those aged 55-64 (4.94), multiracial (12.82), and among those in the Northeast U.S. region (4.12). When considering the U.S. population at large, crude deaths were highest among the following categories: Males (4,692), age group 65+ (2,560), Black/African Americans (3,969), and among those in the South U.S. region (4,025). Generally, amongst demographic groups in the forecasted pandemic period (2020-2022), excess death rates and crude estimates peak in year 2021, highlighting the effectiveness of ongoing dual interventions such as COVID-19 vaccine uptake and improved access to medical care for PWHA after COVID-19 pandemic disruptions settled in 2022 [22].

This analysis uniquely contributes to the literature by quantifying all-cause excess deaths among PWHA during the COVID-19 pandemic via an n-sub-epidemic forecasting method—stratified by race, sex, age, and region. The aforementioned

syndemic conceptual framework [13] not only contextualizes the complex interplay of multiple epidemics but also enhances the interpretive value of our stratified excess mortality estimates. This analysis of all-cause excess mortality incorporates deaths that may have been exacerbated by other interacting syndemic risk factors and thus offers a nuanced quantitative view of how overlapping structural, social, and biological vulnerabilities may have compounded mortality risks in marginalized populations. Our stratified results underscore the need for tailored interventions in future pandemics, especially for populations already burdened by systemic health disparities.

Demographic Disparities

Our study reinforces well-documented disparities in HIV-related outcomes across key demographic groups. HIV is well known to have a disproportionate impact on certain populations, particularly people of color, men who have sex with men, and transgender women. In 2022, Black Americans made up 40% of people living with HIV and 43% of HIV-related deaths, despite representing only 12% of the population. Similarly, Hispanic/Latino individuals comprised 26% of people living with HIV, exceeding their 19% share of the population [23]. The burden is especially severe in the Southern U.S., where eight of the ten states with the highest diagnosis rates are located—driven by limited Medicaid expansion, healthcare provider shortages, low health literacy, and HIV stigma [24,23]. These disparities persist in both infection rates and outcomes, with lower survival rates and higher HIV-related mortality among Black and Latino populations [23]. Well-

established racial barriers to care have been identified as causes of these inequities, including disparate access, knowledge, and prioritization to PrEP and treatment as prevention (TasP) [25,26,27]. These disparities in HIV outcomes cannot be explained by access to care alone; they are also shaped by entrenched systemic issues like racism and stigma surrounding HIV [28,27,24].

While estimates of excess death rates, calculated as the difference between observed and forecasted death rates, may obscure pre-existing demographic disparities in the forecasted rates, those same disparities can still influence the observed death rates. In fact, these disparities may be amplified due to the dual burden of living with HIV/AIDS and experiencing the biological, psychological, social, and systemic impacts of COVID-19.

Literature Comparisons

Comparisons to previously published estimated excess deaths can be made only for 2020, since prior research is limited to that year. When interpreting these comparisons, it is important to recognize key methodological differences. Previous estimates relied primarily on simple comparisons to short historical baselines and were restricted to people living with HIV, excluding individuals diagnosed with AIDS, whereas our approach generates probabilistic counterfactuals conditioned on long-term pre-pandemic trends and includes both PWH and PWA.

In comparison to Viguerie et al. [7], our estimated all-cause crude excess deaths for 2020, when restricted to comparable demographic groups (i.e., individuals with HIV who are Black/African American, Hispanic/Latino, or White; all ages, sexes,

and U.S. regions), was 3,296 (95% PI: 1,150–5,070) (Supplementary-Figure 8), representing a 2.1-fold increase compared to Viguerie et al.'s estimate of 1,550 (95% CI: 1,229–1,877). This difference likely reflects differences in baseline construction, as Viguerie et al. compare 2020 outcomes to 2018–2019 mortality levels, whereas our framework forecasts counterfactual mortality using 12 years of pre-pandemic data (2008–2019) and explicitly propagates uncertainty. Across sex, age, and race strata, this ratio remains broadly consistent, with the upper bound of the Viguerie et al. CI generally falling near or within our 95% PI lower bound [7].

Only a limited comparison can be made to Zhu et al. [6], who estimate COVID-19–specific excess deaths among PWH, rather than all-cause excess mortality. Because their analysis includes all demographic groups without stratification, our 2020 crude excess death estimate (3,622, 95% PI: 2,050–5,287) reflects a 2.5-fold increase over their reported estimate of 1,457 (Supplementary-Figure 5). This difference is expected, as our estimates capture both direct and indirect mortality effects, including deaths from non-COVID-19 causes exacerbated by pandemic-related healthcare disruptions.

Although Ashraf et al. [15] examined only standard (non-excess) HIV-coded death rates through 2020, we observe consistent qualitative trends across sex, age, race, and region when comparing their findings with the fitted and observed trajectories from our models, providing additional face validity.

Taken together, these comparisons indicate that our excess mortality estimates are higher than several previously published values, but this should not be interpreted

as inconsistency or overestimation. Rather, our results represent upper-bound burden estimates that incorporate long-term pre-pandemic trends, multi-year pandemic effects, and uncertainty propagation, offering a complementary perspective to earlier, more conservative approaches. By applying a validated, model-based forecasting framework to all-cause mortality data, we extend prior efforts [16] by capturing trends over a longer time horizon and across key demographic groups, providing a transparent benchmark for future studies of pandemic-related disparities and syndemic impacts.

Limitations

Our study is not exempt from limitations. Because AtlasPlus data are available only as overall or one-way stratified summaries, models were estimated independently by sex, age, race/ethnicity, and region; thus, stratified crude excess deaths are not expected to sum to the overall estimate and should be interpreted as parallel, internally consistent assessments. In addition, all-cause excess mortality could not be disaggregated by cause of death, precluding attribution to HIV/AIDS-, COVID-19-, or other cause-specific pathways [2]. Year-to-year comparisons, particularly between 2020 and 2021, should be interpreted cautiously, as pandemic-related disruptions to HIV testing, diagnosis, reporting, and care likely affected both observed deaths and population denominators, with higher excess mortality in 2021 reflecting delayed care, improved ascertainment, and accumulated indirect effects. Stratification by comorbidities (e.g., cardiovascular disease, diabetes,

mental illness, or substance use disorders) was not feasible due to data aggregation, although these conditions are more prevalent among PWHA and likely contributed to excess mortality. Finally, excess death rates were estimated using a non-negativity constraint consistent with standard burden-of-disease practice, whereby negative deviations were retained at the model-output level but set to zero to avoid overestimating cumulative burden.

Conclusions:

Our results underscore the urgent need to account for the compounded vulnerabilities faced by PWHA during public health crises. By applying a model-based excess mortality framework, we reveal recent mortality patterns that may not be captured by disease-specific mortality reporting alone, thereby quantifying the cumulative impact of overlapping epidemics. Understanding how structural inequities, healthcare disruptions, and broader biopsychosocial stressors influence mortality among PWHA can guide policymakers in designing more equitable and resilient emergency response plans. Taken together, these findings provide actionable evidence to inform future public health programming, resource allocation, and policy decisions aimed at protecting PWHA and other medically vulnerable populations during future pandemics.

Acknowledgements

1. Author Contributions: L.H. performed data analysis and contributed to manuscript drafting and editing. H.K. assisted with generating figures in MATLAB. G.C. conceived the project, provided general guidance, and revised the manuscript.
2. Conflicts of Interest: The authors declare no conflicts of interest.
3. Sources of Funding: No funding was received for this study.
4. Corresponding Author Contact Information:

   Lindsay Hall, lhall63@student.gsu.edu;

   Gerardo Chowell, gchowell@gsu.edu
5. Research presented at Emory University Summer Institute in Statistics and Modeling in Infectious Diseases (SSMID) Conference. July 2025. Atlanta, Georgia, USA.
6. Original data & analytical code can be found at: https://github.com/lhall63/U.S.-Excess-Death-Rates-among-PLHA-during-COVID-19/

References:

[1] Ahmad FB, Cisewski JA. Provisional COVID-19 Mortality Surveillance. National Center for Health Statistics. 2025. DOI: https://dx.doi.org/10.15620/cdc/20250305007

[2] Centers for Disease Control and Prevention (CDC) (2021). HIV Mortality, 2021. [PowerPoint slides] Retrieved from https://www.cdc.gov/hiv-data/media/pdfs/nhss/nhss-surveillance-slideset-mortality-2021.pdf

[3] Bleichrodt, Amanda M.; Okano, Justin T.; Fung, Isaac C.H.; Chowell, Gerardo; Blower, Sally. The future of HIV: challenges in meeting the 2030 Ending the HIV Epidemic in the US (EHE) reduction goal. AIDS 39(6):p 708-718, May 01, 2025. | DOI: 10.1097/QAD.0000000000004122

[4] *Chen, J. T., & Krieger, N. (2021). Revealing the unequal burden of COVID-19 by income, race/ethnicity, and household crowding: US county versus zip code analyses. Journal of Public Health Management and Practice, 27(Supplement 1), S43-S56.*

[5] Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. *AIDS*. 2021;35(4):F1-F10. doi:10.1097/QAD.0000000000002836

[6] Zhu, W., Huang, Y. A., Song, R., Wiener, J., Neblett-Fanfair, R. N., Kourtis, A. P., & Hoover, K. W. (2023). An estimate of excess deaths among people with HIV during the coronavirus disease 2019 pandemic in the United States, 2020. *AIDS (London, England)*, *37*(5), 851–853. https://doi.org/10.1097/QAD.0000000000003503

[7] Viguerie, A., Song, R., Bosh, K., Lyles, C. M., & Farnham, P. G. (2024). *Mortality Among Persons With HIV in the United States During the COVID-*

19 Pandemic: A Population-Level Analysis. Retrieved January 25, 2025, from https://stacks.cdc.gov/view/cdc/159428

[8] Boffito, M., & Waters, L. (2021). More evidence for worse COVID-19 outcomes in people with HIV. *The Lancet HIV*, *8*(11), e661–e662. https://doi.org/10.1016/S2352-3018(21)00272-1

[9] Yang, X., Sun, J., Patel, R. C., Zhang, J., Guo, S., Zheng, Q., Olex, A. L., Olatosi, B., Weissman, S. B., Islam, J. Y., Chute, C. G., Haendel, M., Kirk, G. D., Li, X., Moffitt, R., Akelsrod, H., Crandall, K. A., Francheschini, N., French, E., … Mannon, R. B. (2021b). Associations between HIV infection and clinical spectrum of COVID-19: A population level analysis based on US National COVID Cohort Collaborative (N3C) data. *The Lancet HIV*, *8*(11), e690–e700. https://doi.org/10.1016/S2352-3018(21)00239-3

[10] Jewell, B. L., Mudimu, E., Stover, J., Ten Brink, D., Phillips, A. N., Smith, J. A., ... & Kelly, S. L. (2020). Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. The lancet HIV, 7(9), e629-e640.

[11] Hogan, A. B., Jewell, B. L., Sherrard-Smith, E., Vesga, J. F., Watson, O. J., Whittaker, C., ... & Hallett, T. B. (2020). Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. The Lancet global health, 8(9), e1132-e1141.

[12] Woolf S H, Masters R K, Aron L Y. Effect of the covid-19 pandemic in 2020 on life expectancy across populations in the USA and other high income countries: simulations of provisional mortality data BMJ 2021; 373 :n1343

[13] Shiau, S., Krause, K. D., Valera, P., Swaminathan, S., & Halkitis, P. N. (2020). The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective. *AIDS and Behavior*, *24*(8), 2244–2249. https://doi.org/10.1007/s10461-020-02871-9

[14] Leon, D. A., Shkolnikov, V. M., Smeeth, L., Magnus, P., Pechholdová, M., & Jarvis, C. I. (2020). COVID-19: a need for real-time monitoring of weekly excess deaths. The Lancet, 395(10234), e81.

[15] Ashraf, H., Nadeem, A., Ashfaq, H., Fatima, T., Ahmed, S., Nadeem, Z. A., & Saleh, A. (2024). Disparities in mortality trends of adults with HIV in the USA: A comprehensive examination across 2 decades. *Medicine*, *103*(25), e38570. https://doi.org/10.1097/MD.0000000000038570

[16] Chowell, G., Dahal, S., Bleichrodt, A., Tariq, A., Hyman, J. M., & Luo, R. (2024). *SubEpiPredict:* A tutorial-based primer and toolbox for fitting and forecasting growth trajectories using the ensemble *n*-sub-epidemic modeling framework. *Infectious Disease Modelling*, *9*(2), 411–436. https://doi.org/10.1016/j.idm.2024.02.001

[17] Centers for Disease Control and Prevention (CDC). Technical Notes. 2024. Available at: https://gis.cdc.gov/grasp/nchhstpatlas/main.html. [Accessed 25 February 2025].

[18] Hurvich CM, Tsai CL. Regression and time series model selection in small samples. Biometrika. 1989;76(2):297–307.

[19] Sugiura N. Further analysis of the data by akaike's information criterion and the finite corrections: Further analysis of the data by akaike's. Communications in Statistics-theory and Methods. 1978;7(1):13–26.

[20] Karami, Hamed, Svenn-Erik Mamelund, Alexandra Smirnova, and Gerardo Chowell. *"Global Excess Tuberculosis Mortality During COVID-19: A Country-Level Modeling Study of Policy and Development Correlates." BMC Public Health, 2025.* https://doi.org/10.21203/rs.3.rs-6806070/v1

[21] Hastie T, Tibshirani R, Friedman JH. *The elements of statistical learning: data mining, inference, and prediction.* Springer; 2009.

[22] Mirzaei H, Moradi Y, Abbaszadeh S, et al. The Impact of COVID-19 on Disruptions of HIV-related Services: A Rapid Review. *Med J Islam Repub Iran*. 2022;36:98. Published 2022 Aug 29. doi:10.47176/mjiri.36.98

[23] KFF. (2024, October 15). The impact of HIV on Hispanic/Latino people in the United States. KFF. https://www.kff.org/hivaids/fact-sheet/the-impact-of-hiv-on-hispanic-latino-people-in-the-united-states/

[24] Sullivan, P. S., Satcher Johnson, A., Pembleton, E. S., Stephenson, R., Justice, A. C., Althoff, K. N., Bradley, H., Castel, A. D., Oster, A. M., Rosenberg, E. S., Mayer, K. H., & Beyrer, C. (2021). Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. *Lancet*

(London, England), *397*(10279), 1095–1106. https://doi.org/10.1016/S0140-6736(21)00395-0

[25] Borsa, A., & Siegel, K. (2023). Barriers to Treatment as Prevention Adoption Among Sexual and Gender Minority Individuals Who Have Sex with Men in the United States. *AIDS patient care and STDs*, *37*(5), 268–277. https://doi.org/10.1089/apc.2023.0001

[26] Elopre, L., Ott, C., Lambert, C. C., Amico, K. R., Sullivan, P. S., Marrazzo, J., Mugavero, M. J., & Turan, J. M. (2021). Missed Prevention Opportunities: Why Young, Black MSM with Recent HIV Diagnosis did not Access HIV Pre-exposure Prophylaxis Services. *AIDS and behavior*, *25*(5), 1464–1473. https://doi.org/10.1007/s10461-020-02985-0

[27] Matacotta, J. J., Rosales-Perez, F. J., & Carrillo, C. M. (2020). HIV Preexposure Prophylaxis and Treatment as Prevention - Beliefs and Access Barriers in Men Who Have Sex With Men (MSM) and Transgender Women: A Systematic Review. Journal of patient-centered research and reviews, 7(3), 265–274. https://doi.org/10.17294/2330-0698.1737

[28] Centers for Disease Control and Prevention. (2024). Ending the HIV epidemic in the US: Goals. https://www.cdc.gov/ehe/php/about/goals.html. [Accessed 31 May 2025].



Figure 1. Death Rate for HIV, AIDS, and HIV/AIDS Combined by Year Using Weighted Ensemble Model. This figure represents overall death rate in deaths per 100,000 people.

Legend: The solid red line represents the modeled median death rate, with the dotted black line representing 95% Prediction Interval (PI). Data points shown in black circles represent observed data used for the calibration period, while solid-filled data points in years 2020-2022 represent forecasted data. Forecasted data in green represents excess death rates outside of the 95% PI, while forecasted data in yellow, if present, represents excess data rates within the 95% PI. The blue dotted vertical line denotes year 2019, which is the end of the calibration period, and before COVID-19.



Figure 2 Excess Death Rate for HIV, AIDS, and HIV/AIDS Combined for 2020-2022 Using Weighted Ensemble Forecasting. This figure represents overall excess death rates, expressed per 100,000 people.

The 95% upper and lower bounds for median excess death rates are displayed in black bars.



Figure 3 Excess Death Rate for HIV, AIDS, and HIV/AIDS Combined by Sex for 2020-2022 Using Weighted Ensemble Forecasting. This figure represents excess death rates, expressed per 100,000 people.

The 95% upper and lower bounds for median excess death rates are displayed in black bars.



Figure 4 Excess Death Rate for HIV, AIDS, and HIV/AIDS Combined by Age for 2020-2022 Using Weighted Ensemble Forecasting. This figure represents excess death rates, expressed per 100,000 people.

The 95% upper and lower bounds for median excess death rates are displayed in black bars.



Figure 5 Excess Death Rate for HIV, AIDS, and HIV/AIDS Combined by Race for 2020-2022 Using Weighted Ensemble Forecasting. This figure represents excess death rates, expressed per 100,000 people.

The 95% upper and lower bounds for median excess death rates are displayed in black bars.